Skip to Main Content

Welcome to STAT’s latest e-book.

Drug pricing is an issue that will not go away. Biotech and pharma are the targets of legislation — in the states and in Washington — to bring down rising drug prices. Health plans want to see prices tied to “value.” And patients are looking north to Canada for relief, or even Egypt to get their hands on pricey drugs — and a trip to the pyramids, too.

Amazon may enter the fray, drug ads are being spoofed, and one pharma CEO blames Europe.

Meanwhile, Americans want their government to do something. Just what that would be is up for debate. Read what STAT reporters have discovered in untangling this knotty problem.